Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
|Articles|May 15, 2017

BioPharm International

  • BioPharm International-05-15-2017
  • Volume 2017 eBook
  • Issue 1

Insourcing vs Outsourcing: Choosing the Right Strategy

Author(s)Oskar Gold

The article reviews strategies for firms with or without existing in-house capacities and the pros and cons for outsourcing bio/pharmaceutical development and manufacturing.

Aseptic manufacturing is an important part of drug development and commercialization that must be approached with utmost care and attention to detail. Getting a drug product packaged and passing successfully through clinical manufacturing and into the marketplace will depend on many factors, some which are fundamental and straightforward while others require careful consideration of different criteria that can affect each individual situation. The article reviews strategies for firms with or without existing in-house capacities and the pros and cons for outsourcing bio/pharmaceutical development and manufacturing.

 

Download BioPharm International's

2017 Outsourcing Resources eBook

.

 

 

 

 


Related to this article

The BioPharm Brief: FDA’s Fast-Track Pilot Reportedly Stalls, a Long-Acting Bispecific for Atopic Dermatitis, and a Twice-Yearly Obesity Approach
FDA has reportedly shelved its Commissioner’s National Priority Voucher pilot and paused publishing complete response letters, Zai Lab’s IL-13/IL-31Rα bispecific ZL-1503 shows a 40- to 50-day half-life that points to dosing every 12 weeks, and Wave Life Sciences reports 1-year INLIGHT data for its INHBE-silencing siRNA WVE-007 in obesity.